Pasar al contenido principal

ANALISIS DE LAS BASES MOLECULARES DE LA INTERACCION SARS-COV-2 Y LA CELULA HUESPED A NIVEL PROTEOMICO. UNA PLATAFORMA TECNOLOGICA PARA COMBATIR ESTA Y FUTURAS PANDEMIAS

PID2021-127496NB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discrimination of Etiologically Different Cholestasis by Modeling Proteomics Datasets

  • Guerrero, Laura
  • Vindel-Alfageme, Jorge
  • Hierro, Loreto
  • Stark, Luiz
  • Vicent, David
  • Sorzano, Carlos Óscar S.
  • Corrales, Fernando J.
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Cholestasis is characterized by disrupted bile flow from the liver to the small intestine. Although etiologically different cholestasis displays similar symptoms, diverse factors can contribute to the progression of the disease and determine the appropriate therapeutic option. Therefore, stratifying cholestatic patients is essential for the development of tailor-made treatment strategies. Here, we have analyzed the liver proteome from cholestatic patients of different etiology. In total, 7161 proteins were identified and quantified, of which 263 were differentially expressed between control and cholestasis groups. These differential proteins point to deregulated cellular processes that explain part of the molecular framework of cholestasis progression. However, the clustering of different cholestasis types was limited. Therefore, a machine learning pipeline was designed to identify a panel of 20 differential proteins that segregate different cholestasis groups with high accuracy and sensitivity. In summary, proteomics combined with machine learning algorithms provides valuable insights into the molecular mechanisms of cholestasis progression and a panel of proteins to discriminate across different types of cholestasis. This strategy may prove useful in developing precision medicine approaches for patient care., The CNB was supported by Comunidad de Madrid Grants B2017/BMD-3817 and 2022/BMD-7232. Severo Ochoa Project SEV 2017-0712. Intramural CSIC PIE/COVID-19 projects 202020E079 and 202020E108. MICIN PID2021-127496NB-100. ISCIII FIS PI15/01127. This research work was also funded by the European Commission—NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). This research work was also funded by the European Commission—NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Refinement of paramagnetic bead-based digestion protocol for automatic sample preparation using an artificial neural network

  • Ciordia, Sergio
  • Santos, Fátima M.
  • Dias, João M. L.
  • Lamas, José Ramón
  • Paradela, Alberto
  • Alvarez-Sola, Gloria
  • Ávila, Matías A.
  • Corrales, Fernando J.
Despite technological advances in the proteomics field, sample preparation still represents the main bottleneck in mass spectrometry (MS) analysis. Bead-based protein aggregation techniques have recently emerged as an efficient, reproducible, and high-throughput alternative for protein extraction and digestion. Here, a refined paramagnetic bead–based digestion protocol is described for Opentrons® OT-2 platform (OT-2) as a versatile, reproducible, and affordable alternative for the automatic sample preparation for MS analysis. For this purpose, an artificial neural network (ANN) was applied to maximize the number of peptides without missed cleavages identified in HeLa extract by combining factors such as the quantity (μg) of trypsin/Lys-C and beads (MagReSyn® Amine), % (w/v) SDS, % (v/v) acetonitrile, and time of digestion (h). ANN model predicted the optimal conditions for the digestion of 50 μg of HeLa extract, pointing to the use of 2.5% (w/v) SDS and 300 μg of beads for sample preparation and long-term digestion (16h) with 0.15 μg Lys-C and 2.5 μg trypsin (≈1:17 ratio). Based on the results of the ANN model, the manual protocol was automated in OT-2. The performance of the automatic protocol was evaluated with different sample types, including human plasma, Arabidopsis thaliana leaves, Escherichia coli cells, and mouse tissue cortex, showing great reproducibility and low sample-to-sample variability in all cases. In addition, we tested the performance of this method in the preparation of a challenging biological fluid such as rat bile, a proximal fluid that is rich in bile salts, bilirubin, cholesterol, and fatty acids, among other MS interferents. Compared to other protocols described in the literature for the extraction and digestion of bile proteins, the method described here allowed identify 385 unique proteins, thus contributing to improving the coverage of the bile proteome., This work was supported by the following grants. Comunidad de Madrid Grants B2017/BMD-3817 and 2022/BMD-7232. Severo Ochoa Project SEV 2017-0712. Intramural CSIC PIE/COVID-19 projects 202020E079 and 202020E108. MICIN PID2021-127496NB-100. This research work was also funded by the European Commission—NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). Project PI16/01126 from Instituto de Salud Carlos III (ISCIII) co-financed by “Fondo Europeo de Desarrollo Regional” (FEDER) “Una manera de hacer Europa”. Grants 2020/101 and 2023/2, Bilebank 1.0 and 2.0, from Euroregion Nouvelle Aquitaine-Euskadi-Navarra., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Molecular Insights of Cholestasis in MDR2 Knockout Murine Liver Organoids

  • Blázquez-García, Irene
  • Guerrero, Laura
  • Cacho-Navas, Cristina
  • Djouder, Nabil
  • Millan, Jaime
  • Paradela, Alberto
  • Carmona-Rodríguez, Lorena
  • Corrales, Fernando J.
MDR3 (multidrug resistance 3) deficiency in humans (MDR2 in mice) causes progressive familial intrahepatic cholestasis type 3 (PFIC3). PFIC3 is a lethal disease characterized by an early onset of intrahepatic cholestasis progressing to liver cirrhosis, a preneoplastic condition, putting individuals at risk of hepatocellular carcinoma (HCC). Hepatocyte-like organoids from MDR2-deficient mice (MDR2KO) were used in this work to study the molecular alterations caused by the deficiency of this transporter. Proteomic analysis by mass spectrometry allowed characterization of 279 proteins that were differentially expressed in MDR2KO compared with wild-type organoids. Functional enrichment analysis indicated alterations in three main cellular functions: (1) interaction with the extracellular matrix, (2) remodeling intermediary metabolism, and (3) cell proliferation and differentiation. The affected cellular processes were validated by orthogonal molecular biology techniques. Our results point to molecular mechanisms associated with PFIC3 that may drive the progression to liver cirrhosis and HCC and suggest proteins and cellular processes that could be targeted for the development of early detection strategies for these severe liver diseases., The CNB was supported by Comunidad de Madrid Grants B2017/BMD-3817 and 2022/BMD-7232. Severo Ochoa Project SEV 2017-0712. Intramural CSIC PIE/COVID-19 projects 202020E079 and 202020E108. MICIN PID2021- 127496NB-100 (F.J.C.) and PID2020-119881RB-I00 (J.M). This research work was also funded by the European Commission�NextGenerationEU (Regulation EU 2020/ 2094), through CSIC’s Global Health Platform (PTI Salud Global)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Molecular basis of progressive familial intrahepatic cholestasis 3. A proteomics study

  • Guerrero, Laura
  • Carmona-Rodríguez, Lorena
  • Santos, Fátima M.
  • Ciordia, Sergio
  • Stark, Luiz
  • Hierro, Loreto
  • Pérez-Montero, Pablo
  • Vicent, David
  • Corrales, Fernando J.
Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a severe rare liver disease that affects between 1/50,000 and 1/100,000 children. In physiological conditions, bile is produced by the liver and stored in the gallbladder, and then it flows to the small intestine to play its role in fat digestion. To prevent tissue damage, bile acids (BAs) are kept in phospholipid micelles. Mutations in phosphatidyl choline transporter ABCB4 (MDR3) lead to intrahepatic accumulation of free BAs that result in liver damage. PFIC3 onset usually occurs at early ages, progresses rapidly, and the prognosis is poor. Currently, besides the palliative use of ursodeoxycholate, the only available treatment for this disease is liver transplantation, which is really challenging for short-aged patients. To gain insight into the pathogenesis of PFIC3 we have performed an integrated proteomics and phosphoproteomics study in human liver samples to then validate the emerging functional hypotheses in a PFIC3 murine model. We identified 6246 protein groups, 324 proteins among them showing differential expression between control and PFIC3. The phosphoproteomic analysis allowed the identification of 5090 phosphopeptides, from which 215 corresponding to 157 protein groups, were differentially phosphorylated in PFIC3, including MDR3. Regulation of essential cellular processes and structures, such as inflammation, metabolic reprogramming, cytoskeleton and extracellular matrix remodeling, and cell proliferation, were identified as the main drivers of the disease. Our results provide a strong molecular background that significantly contributes to a better understanding of PFIC3 and provides new concepts that might prove useful in the clinical management of patients., Centro Nacional de Biotecnología. Grant Numbers: 202020E079, 202020E108, EU 2020/2094 Ministerio de Ciencia e Innovación. Grant Number: PID2021-127496NB-100 Comunidad de Madrid. Grant Numbers: 2022/BMD-7232, B2017/BMD-3817 European Commission—NextGenerationEU. Grant Number: 2020/2094, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

  • Clavería-Cabello, Alex
  • Herranz, Jose Maria
  • Latasa, Maria Ujue
  • Arechederra, Maria
  • Uriarte, Iker
  • Pineda-Lucena, Antonio
  • Prosper, Felipe
  • Berraondo, Pedro
  • Alonso, Cristina
  • Sangro, Bruno
  • García Marin, Jose Juan
  • Martinez-Chantar, Maria Luz
  • Ciordia, Sergio
  • Corrales, Fernando J.
  • Francalanci, Paola
  • Alaggio, Rita
  • Zucman-Rossi, Jessica
  • Indersie, Emilie
  • Cairo, Stefano
  • Domingo-Sàbat, Montserrat
  • Zanatto, Laura
  • Sancho-Bru, Pau
  • Armengol, Carolina
  • Berasain, Carmen
  • Fernández-Barrena, Maite G.
  • Ávila, Matias Antonio
Supplementary data to this article can be found online at https://doi.org/10.1016/ j.jhep.2023.05.031, Hepatoblastoma (HB) is the most frequent childhood liver cancer. Patients with aggressive tumors have limited therapeutic options; therefore, a better understanding of HB pathogenesis is needed to improve treatment. HBs have a very low mutational burden; however, epigenetic alterations are increasingly recognized. We aimed to identify epigenetic regulators consistently dysregulated in HB and to evaluate the therapeutic efficacy of their targeting in clinically relevant models., This work was supported by grants from the Scientific Foundation of the Spanish Association Against Cancer (AECC) LABAE20011GARC (MGFB), PROYE19044SANC (PSB), and Innova-INNOV211822SANJ (FP). Grants from Ministerio de Ciencia, Innovación y Universidades MICINN-Agencia Estatal de Investigación integrado en el Plan Estatal de Investigación Científica y Técnica y Innovación, cofinanciado con Fondos FEDER PID2019-104878RB-100/AEI/10.13039/501100011033 (MAA), PID2020-117116RB-I00 (MGFB), PID2021-127496NB-100 (FJC), PID2020-115875RB-100/AEI/10.13039/501100011033 (APL), and PID2020-117116RB-I00 (MLMC). Intramural CSIC PIE/COVID-19 projects 202020E079 and 202020E108; Comunidad de Madrid Grant B2017/BMD-3817; Severo Ochoa Project SEV 2017-0712; European Commission-NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global) (FJC). Instituto de Salud Carlos III (ISCIII) CIBERONC CB16/12/00489 (FP). Navarra Government Department of Health (44/2021) (also co-financed by FEDER) and Department of Economic Development AGATA (0011-1411-2020-000011 and 0011-1411-2020-000010) (FP). Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain (PI19/00819 and PI22/00526 co-funded by European Regional Development Fund/European Social Fund, “Investing in your future”); Junta de Castilla y Leon (SA074P20) and Fundació Marato TV3 (Ref. 201916/31) (JJGM). European Union's Horizon 2020 research and innovation program under grant agreement N° 668596 (ChiLTERN) and N° 826121 (iPC) and AGAUR (2017-SGR-490) (CA). Ligue contre le cancer (équipe labellisée), SFCE (Société Française de Lutte Contre les Cancers et les Leucémies de l’Enfant), the SIRIC CARPEM, PeLiCan.Resist InCa (Pediatric LIver CANcer database to combat RESISTance to treatment, Institut National du Cancer), France Génomique, association Etoile de Martin, Fédération Enfants et Santé, association Hubert Gouin “Enfance et Cancer,” INSERM Plan Cancer (JZR). FIMA pre-doctoral fellowship to ACC, AECC post-doctoral fellowship POSTD18014AREC to MA and Ramón y Cajal Program contracts RYC-2010-07249 (CA) and RYC2018-024475-1 (MGFB) from the Spanish Ministry of Science and Innovation. This work was supported by a grant (PRYCO223102ARME) from the Scientific Foundation of the AECC (CA, MAA, MLMC, PSB, JJGM), grant EDH22PI01 from CIBERehd (CA, MAA, JJGM, PB). Grants from Fundación Eugenio Rodríguez Pascual; Fundación Echébano; Fundación Mario Losantos, Fundación M Torres (MAA, CB, MGFB)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mapping early serum proteome signatures of liver regeneration in living donor liver transplant cases

  • Carmona-Rodríguez, Lorena
  • Gajadhar, Aaron S.
  • Blázquez-García, Irene
  • Guerrero, Laura
  • Fernández-Rojo, Manuel A.
  • Uriarte, Iker
  • Mamani-Huanca, Maricruz
  • López-Gonzálvez, Ángeles
  • Ciordia, Sergio
  • Ramos, Antonio
  • Herrero, José Ignacio
  • Fernández-Barrena, Maite G.
  • Arechederra, María
  • Berasain, Carmen
  • Quiroga, Jorge
  • Sangro, Bruno
  • Argemi, Josepmaría
  • Pardo, Fernando
  • Rotellar, Fernando
  • López-Serrano, Daniel
  • Barbas, Coral
  • Ávila, Matías A.
  • Corrales, Fernando J.
The liver is the only solid organ capable of regenerating itself to regain 100% of its mass and function after liver injury and/or partial hepatectomy (PH). This exceptional property represents a therapeutic opportunity for severe liver disease patients. However, liver regeneration (LR) might fail due to poorly understood causes. Here, we have investigated the regulation of liver proteome and phosphoproteome at a short time after PH (9 h), to depict a detailed mechanistic background of the early LR phase. Furthermore, we analyzed the dynamic changes of the serum proteome and metabolome of healthy living donor liver transplant (LDLT) donors at different time points after surgery. The molecular profiles from both analyses were then correlated. Insulin and FXR-FGF15/19 signaling were stimulated in mouse liver after PH, leading to the activation of the main intermediary kinases (AKT and ERK). Besides, inhibition of the hippo pathway led to an increased expression of its target genes and of one of its intermediary proteins (14-3-3 protein), contributing to cell proliferation. In association with these processes, metabolic reprogramming coupled to enhanced mitochondrial activity cope for the energy and biosynthetic requirements of LR. In human serum of LDLT donors, we identified 56 proteins and 13 metabolites statistically differential which recapitulate some of the main cellular processes orchestrating LR in its early phase. These results provide mechanisms and protein mediators of LR that might prove useful for the follow-up of the regenerative process in the liver after PH as well as preventing the occurrence of complications associated with liver resection., The CNB was supported by Comunidad de Madrid Grants B2017/BMD-3817 and 2022/BMD-7232. Severo Ochoa Pro- ject SEV 2017-0712. Intramural CSIC PIE/COVID-19 pro- jects 202020E079 and 202020E108. MICIN PID2021-127496NB-100. This research work was also funded by the European Commission—NextGenerationEU (Regulation EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global). Lorena Carmona-Rodríguez and Fernando J. Corrales belong to the Spanish National Research Council (CSIC)'s Cancer Hub., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeted Quantitative Analysis of Specific Proteins in Cytosolic, Mitochondrial, and Nuclear Fractions Using PRM

  • Delgado-Sequera, Alejandra
  • Paradela, Alberto
  • Corrales, Fernando J.
Data are available in the PRIDE repository under accession number PXD067737., Mitochondria play a central role in liver physiology by regulating key metabolic processes. Consequently, mitochondrial dysfunction is a hallmark of multiple liver diseases, including steatosis, steatohepatitis, and liver failure following hepatectomy. Subcellular fractionation is widely used to isolate mitochondria from liver cells or tissue; however, the enrichment and purity of isolated fractions are critical to ensure reliable downstream functional and proteomic analyses. Conventional validation methods, such as immunoblotting of organelle-specific markers, are limited by low throughput, restricted sensitivity, and variability. In this study, we present a targeted proteomics strategy based on parallel reaction monitoring (PRM) to quantitatively assess the enrichment of cytosolic, mitochondrial, and nuclear fractions obtained from liver samples using commercial isolation kits. PRM analyses demonstrated robust and compartment-specific enrichment in both PLC/PRF/5 cells and mouse liver tissue. In PLC/PRF/5 cells, high nuclear/cytosolic enrichment was observed for Prelamin A/C, while mitochondrial markers such as ATPase showed strong mitochondrial/cytosolic ratios. Cytosolic markers consistently displayed enrichment in the cytosolic fraction. Similar trends were observed in mouse liver tissue, confirming applicability across biological systems. Overall, these results highlight PRM as a sensitive, reproducible, and cost-effective alternative to immunodetection approaches for evaluating subcellular fraction purity, supporting high-quality mitochondrial preparations for translational hepatology studies., The CNB was supported by grant CEX2023–001386-S funded by MICIU/AEI/10.13039/501100011033. Comunidad de Madrid grants B2017/BMD-3817 and 2022/BMD-7232. Intramural CSIC PIE/COVID-19 projects 202020E079 and 202020E108. MICIN PID2021–127496NB-100. This research work was also funded by the European Commission─NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global) and Conexión Cancer., Peer reviewed, Modelo experimental animal, Mamíferos - Roedores
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma

  • Lopez-Pascual, Amaya
  • Elurbide, Jasmin
  • Valbuena-Goiricelaya, Emiliana
  • Latasa, M Ujue
  • Anaya, Elena
  • Adan-Villaescusa, Elena
  • Castelló-Uribe, Borja
  • Martínez-Pérez, Luz A
  • Uriarte, Iker
  • Arechederra, Maria
  • Ciordia, Sergio
  • Corrales, Fernando J.
  • Strnad, Pavel
  • Frankova, Sona
  • Sticova, Eva
  • Fabian, Ondrej
  • Colyn, Leticia
  • Inacio, Patricia
  • Bayo, Juan
  • Huch, Meritxell
  • Berasain, Carmen
  • Fernández-Barrena, Maite G
  • Avila, Matías A
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2026.1765945/full#supplementary-material, Epigenetic alterations play an increasingly recognized role in carcinogenesis and in the development of resistance to anticancer therapies. Epigenetic enzymes (writers and erasers) and effectors (readers) are largely influenced by the availability of metabolites generated through one-carbon metabolism (OCM), the tricarboxylic acid (TCA) cycle, and acetyl-CoA synthesis (ACS). In this study we examined the expression of epigenetic and metabolic genes to investigate their interplay in cholangiocarcinoma (CCA)., The author(s) declared that financial support was received for this work and/or its publication. This work was supported by: grants from Ministerio de Ciencia, Innovación y Universidades MICIU/AEI: PID2022-136616OB-I00/AEI/10.13039/501100011033 (M.A.A.); PID2021-127496NB-100 (F.J.C) and CEX2023-001386-S 10.13039/501100011033 (F.J.C.) integrados en el Plan Estatal de Investigación Científica y Técnica e Innovación, cofinanciado con Fondos FEDER “Una manera de hacer Europa”; grant ERA-NET TRANSCAN-3 TRANSCAN2022-784-024 (M.A.A.); grant from European Commission NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global) and Conexión Cancer; grant from the Instituto de Salud Carlos III (ISCIII) AC23_1/00008 (M.A.A.); grant from Scientific Foundation of the Spanish Association Against Cancer (FAECC) LABAE20011GARC (M.G.F-B.) and ERA-NET TRANSCAN-3 TRANSCAN2022-784-024; grant from Fundación Eugenio Rodriguez Pascual 2022 (M.A.A. and M.G.F-B.); grant 2022/BMD-7232 from Comunidad de Madrid, Spain (F.J.C.), ERA-NET TRANSCAN2022-784-024 (P.S). A.L.-P. receives a Sara Borrell Contract from the Spanish Ministry of Health (CD22/00109). J.E. receives a contract from ERA-NET TRANSCAN-3 FAECC (TRNSC235657AVIL); E.V-G. receives a predoctoral fellowship from the Ministerio de Ciencia, Innovación y Universidades (PREP2022-000609) project PID2022-136616OB-I00, from MICIN/AEI. E.A-V. receives a predoctoral fellowship from the Ministerio de Ciencia, Innovación y Universidades, Programa de Formación del Profesorado Universitario (FPU23/00176). B.C-U receives a predoctoral Juan Serra fellowship. L.A.M-P receives a post-doctoral fellowship from CONAHCYT, Mexico. M.A. receives a researcher contract from FAECC (INVES223049AREC). R.A-B and M.H are funded by the Max Planck Gesellschafts, and the BMBF (LiSYM-KREBS, DEEP-HCC). This study is based upon work from COST Action Precision-BTC-Network CA22125, supported by COST., Peer reviewed, Modelo experimental animal, Mamíferos - Roedores